Procter & Gamble Health Limited (PGHL) Fair Value & Analysis
Healthcare · IN · Market cap ₹106B
Fair value as of: Aug 13, 2026
From 26 valuation models · updated 4 days ago
Fair value updated Aug 13, 2026, revised from ₹3,533 to ₹5,073 (+43.6%) since Aug 8, 2026. Share price −14.2% over the past month.
A strong business, but screening 13% overvalued on our models.
What matters now
- A fairly wide model range (₹3,280 to ₹7,064) leaves room in how you read the outcome.
- Our model range runs from ₹3,280 (bear) to ₹7,064 (bull), base ₹5,073. The closer the price sits to the lower half, the larger the margin of safety.
- Quality 93/100 (high quality) with high evidence: the data supports the verdict.
Price vs Fair Value (5 years)
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Aug 13, 2026.
How to read this chart
60‑month range ₹3,484 – ₹6,919 · fair‑value band ₹3,280 – ₹7,064 · the ₹5,837 price screens above the ₹5,073 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Aug 13, 2026.
Analysis
Procter & Gamble Health Limited (PGHL) currently trades at ₹5,837, while our model-based Fair Value estimate is ₹5,073, implying the stock looks roughly 13.1% overvalued today. The Quality Score stands at 93/100 (high quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium, the entry price still matters most (evidence: high).
Over the trailing twelve months, Procter & Gamble Health Limited generated revenue of ₹14.1B at a net margin of 23.2%. Revenue grew 19.1% year over year. It earns a return on equity of 61.6%. The balance sheet holds a net cash position of ₹1.8B. Fundamentals as of Aug 13, 2026
Our scenario range runs from ₹3,280 (bear case) to ₹7,064 (bull case); at ₹5,837, the current price sits within that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades about 13% below its 52-week high and 24% above its 52-week low, currently above its 200-day average. For context, the median of 10 Healthcare peers we cover trades at -49% fair-value upside, at -13%, PGHL screens cheaper than that median.
Fair Value models
Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.
All 26 models by family
Widest divergence: Growth Earnings (₹3,937) versus Asset-Based (₹211.72). Highest evidence: Growth DCF (80).
Notify me when PGHL reaches fair value
Free. You confirm by email (double opt-in) and can unsubscribe anytime in one click.
Key figures & financial health
More key figures
Figures from reported company fundamentals · as of Aug 13, 2026. TTM = trailing twelve months.
Quality Score breakdown
Of which business quality 87 · Market factors (momentum, volatility) 63
Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.
About the company
Procter & Gamble Health Limited manufactures and markets pharmaceuticals and chemical products in India and internationally. The company offers over-the-counter products, vitamins, minerals, and supplements. It offers its products under the Polybion, Cosome, Evion, Neurobion, Nasivion, Livogen, and Seven Seas brands.
Full company description
Procter & Gamble Health Limited manufactures and markets pharmaceuticals and chemical products in India and internationally. The company offers over-the-counter products, vitamins, minerals, and supplements. It offers its products under the Polybion, Cosome, Evion, Neurobion, Nasivion, Livogen, and Seven Seas brands. The company was formerly known as Merck Limited and changed its name to Procter & Gamble Health Limited in May 2019. Procter & Gamble Health Limited was incorporated in 1967 and is headquartered in Mumbai, India. Procter & Gamble Health Limited is a subsidiary of Procter & Gamble Overseas India B.V.
Company description, as reported by the company or data provider.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
Procter & Gamble Health Limited reported revenue of ₹14.1B in FY2025 versus ₹11.1B in FY2021, a compound +6.0%/yr. Reported net income was ₹3.3B in FY2025, compounding +14.2%/yr from FY2021.
of which total revenue +3.4 pp · buybacks/dilution +0.0 pp
Absolute contributions in percentage points per year; they sum to the EPS growth rate. Start and end points are 3-year averages (details on hover).
PGHL screens 13% overvalued. Compare with Jiangsu Hengrui Pharmaceuticals Co →
Peer Group
Drug Manufacturers - Specialty & Generic · 625 stocks
How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.
Valuation Multiples vs Drug Manufacturers - Specialty & Generic median · lower = cheaper
Snowflake
Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
ESG scores are not available for this stock yet. Values and ESG data are contextual and can differ between providers.
Similar stocks
10 more Drug Manufacturers - Specialty & Generic stocks, each showing price versus our Fair Value estimate (as of Aug 13, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Jiangsu Hengrui Pharmaceuticals Co 600276 | ¥53.76 | ¥25.94 | -52% |
| Sun Pharmaceutical Industries Limited SUNPHARMA | ₹1,944 | ₹989.50 | -49% |
| Divi's Laboratories Limited DIVISLAB | ₹8,500 | ₹1,932 | -77% |
| Torrent Pharmaceuticals Limited TORNTPHARM | ₹4,915 | ₹1,163 | -76% |
| PharmaEssentia Corporation 6446 | 1,440 TWD | 233.93 TWD | -84% |
| Cipla Limited CIPLA | ₹1,463 | ₹1,001 | -32% |
| Zydus Lifesciences Limited ZYDUSLIFE | ₹1,167 | ₹703.32 | -40% |
| Lupin Limited LUPIN | ₹2,281 | ₹2,477 | +9% |
| Mankind Pharma Limited MANKIND | ₹2,433 | ₹983.11 | -60% |
| Dr. Reddy's Laboratories Limited DRREDDY | ₹1,200 | ₹874.79 | -27% |
Compare Procter & Gamble Health Limited with another stock
Price, fair value, quality and upside side by side.
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is Procter & Gamble Health Limited (PGHL) overvalued or undervalued?
What is the fair value of PGHL?
What is the quality score of PGHL?
What is the revenue of Procter & Gamble Health Limited (PGHL)?
What is the net profit margin of PGHL?
Does Procter & Gamble Health Limited pay a dividend?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.
Track Procter & Gamble Health Limited and try Pro for 14 days
One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.
Zero risk: nothing is ever charged. After 14 days you decide whether to stay.